Aptevo Therapeutics

Historical price data

Aptevo Therapeutics is a Seattle-based biotech focused on developing next-generation, multi-specific antibody therapies for cancer. The company's core strategy is its proprietary protein engineering platform, which enables the rational design of T-cell engagers and co-stimulatory molecules with tunable properties to potentially overcome limitations of current immunotherapies. Its most advanced asset, mipletamig (APVO436), is a CD3xCD123 bispecific in Phase 1/2 development for acute myeloid leukemia (AML). Operating as a lean, publicly-traded entity, Aptevo aims to advance its broad, early-stage pipeline through clinical validation and strategic partnerships.

Proprietary protein engineering platform for designing bispecific and trispecific antibodies with tunable affinities and unique geometries, enabling the creation of T-cell engagers and co-stimulatory agonists aimed at improving therapeutic index.

Aptevo competes in the crowded bispecific and T-cell engager arena against giants like Amgen, Genentech, and Johnson & Johnson, plus numerous clinical-stage biotechs. Its differentiation hinges on demonstrating that its platform's design features—low-affinity CD3, tumor-targeted co-stimulation, dual MOA—translate to superior efficacy or safety in clinical trials.